Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Multiple Myeloma

Focus on symptom control – treatment options at a glance

    • Education
    • Hematology
    • Oncology
    • RX
  • 2 minute read

One of the most important decisions that must be made at the onset of symptomatic myeloma is that of adequate therapy. While not yet curable, a number of good options exist that can delay progression. Based on intensive research and better understanding of the pathophysiology, effective treatment options could be added to chemotherapy.

Not all multiple myeloma requires therapy from the outset. If there are no clinical signs yet, the patient can be closely monitored and observed for the time being. However, as soon as bone changes become apparent, for example, effective treatment is indicated. Symptomatic disease is present when the CRAB criteria are met: C = elevated blood calcium concentration (hypercalcemia), R = renal dysfunction (renal insufficiency), A = anemia, B = bone destruction ( Table 1) . In order to decide on a suitable therapy regime, staging and prognostic classification are essential. The goal is to improve myeloma symptomatology, lower M protein, and thus control the disease.

 

 

The various therapeutic approaches are based on conventional chemotherapy, high-dose chemotherapy with autologous blood stem cell transplantation, and newer substances such as bortezomib, lenalidomide, thalidomide, or antibodies (overview 1) . In order to achieve the greatest possible effect against the tumor cells during chemotherapy and at the same time reduce side effects, combinations of cytostatic drugs with different effects are frequently used. However, high-dose chemotherapy with autologous stem cell transplantation is the treatment of choice for patients up to about 70 years of age. Success also depends on the choice of treatment before and after chemotherapy. A combination of the two most important substance classes, proteasome inhibitors and immunomodulators, seems promising for this purpose.

 

 

Established and effective

Thalidomide, bortezomib, lenalidomide have already been shown to be effective in multiple therapeutic regimens, although thalidomide is now rarely used. As a proteasome inhibitor, bortezomib has a high response rate in primary and relapse therapy. Among other things, it blocks the activation of certain signaling pathways as well as DNA repair mechanisms in the myeloma cell so that the cells’ resistance to cytostatic drugs can be overcome. As a triple combination, bortezomib is often used with dexamethasone and cyclophosphamide. Lenalidomide belongs to the group of immunomodulators. It impairs the release of pro-inflammatory substances and increases the production of anti-inflammatory substances.

For the treatment of elderly patients >70 years or sufferers with many comorbidities, the only option for a long time was a combination therapy of melphalan and prednisone. A significant improvement in efficacy was achieved by adding bortezomib. This combination resulted in a significant improvement in the prognosis of affected patients compared with MP. Recent results suggest that an extension of this treatment regimen to include an antibody could lead to further improvement in therapeutic outcomes.

 

Further reading:

  • https://multiples-myelom.ch/de/multiples-myelom/therapien/ (last accessed on 05.08.2020)
  • https://lymphome.de/multiples-myelom/therapie/ (last accessed on 05.08.2020)
  • www.myelom-deutschland.de/das-multiple-myelom/therapie-des-multiplen-myeloms (last accessed on 05.08.2020)
  • www.krebsgesellschaft.de/onko-internetportal/basis-informationen-krebs/krebsarten/multiples-myelom-plasmozytom-morbus-kahler/therapie.html (last accessed on 05.08.2020)

 

InFo ONCOLOGY & HEMATOLOGY 2020; 8(4): 16.

Autoren
  • Leoni Burggraf
Publikation
  • InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
  • Immunomodulators
  • Multiple Myeloma
  • Proteasome Inhibitors
Previous Article
  • From symptom to diagnosis

Mammary tumors of the male

  • Cases
  • Education
  • Oncology
  • Radiology
  • RX
View Post
Next Article
  • Mental health

Modern treatment options for common anxiety disorders

  • Congress Reports
  • General Internal Medicine
  • Psychiatry and psychotherapy
  • RX
View Post
You May Also Like
View Post
  • 6 min
  • EHA 2025

Progress in multiple myeloma

    • Congress Reports
    • Hematology
    • Oncology
    • RX
    • Studies
View Post
  • 6 min
  • Interstitial lung diseases

Artificial intelligence improves ILD diagnosis

    • Education
    • General Internal Medicine
    • Pneumology
    • Prevention and health care
    • RX
    • Studies
View Post
  • 7 min
  • Management of patients after alloHCST

ERS/EBMT guideline recommendations on pulmonary cGvHD

    • Education
    • General Internal Medicine
    • Genetics
    • Hematology
    • Pneumology
    • RX
    • Studies
View Post
  • 3 min
  • Pyoderma gangraenosum

New study data confirm the validity of the PARACELSUS score

    • Congress Reports
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Geriatrics
    • Orthopedics
    • Prevention and health care
    • RX
    • Studies
    • Surgery
View Post
  • 8 min
  • Progressive multiple sclerosis

New horizons: from BTK inhibitors to remyelination

    • Education
    • Genetics
    • Neurology
    • RX
    • Studies
View Post
  • 6 min
  • Cutaneous and especially facial metastases

Rare manifestations of esophageal carcinoma

    • Cases
    • Dermatology and venereology
    • Education
    • Gastroenterology and Hepatology
    • Oncology
    • RX
    • Surgery
View Post
  • 7 min
  • Rare pulmonary syndromes

Yellow nail and Swyer-James syndrome

    • CME continuing education
    • Dermatology and venereology
    • General Internal Medicine
    • Infectiology
    • Pneumology
    • RX
View Post
  • 3 min
  • IMCAS Refresher: Aging Sciences/Plastic Surgery

Trends in aesthetic and regenerative medicine

    • Congress Reports
    • Dermatology and venereology
    • RX
    • Surgery
Top Partner Content
  • Herpes zoster

    Zum Thema
Top CME content
  • 1
    Yellow nail and Swyer-James syndrome
  • 2
    Individual therapy management for an optimized outcome – an update
  • 3
    Doing sport without fear or risk
  • 4
    UV protection and skin cancer screening – Update 2025
  • 5
    Rare malignancy from a dermatological perspective

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.